U.S. Markets closed
  • S&P Futures

    3,576.00
    -25.50 (-0.71%)
     
  • Dow Futures

    28,669.00
    -132.00 (-0.46%)
     
  • Nasdaq Futures

    10,910.50
    -125.00 (-1.13%)
     
  • Russell 2000 Futures

    1,658.50
    -11.30 (-0.68%)
     
  • Crude Oil

    81.59
    +2.10 (+2.64%)
     
  • Gold

    1,672.60
    +0.60 (+0.04%)
     
  • Silver

    19.07
    +0.03 (+0.14%)
     
  • EUR/USD

    0.9795
    -0.0006 (-0.0588%)
     
  • 10-Yr Bond

    3.8040
    +0.0570 (+1.52%)
     
  • Vix

    31.62
    -0.22 (-0.69%)
     
  • GBP/USD

    1.1129
    -0.0038 (-0.3361%)
     
  • USD/JPY

    144.6250
    -0.1040 (-0.0719%)
     
  • BTC-USD

    19,074.51
    -235.95 (-1.22%)
     
  • CMC Crypto 200

    432.82
    -10.61 (-2.39%)
     
  • FTSE 100

    6,893.81
    +12.22 (+0.18%)
     
  • Nikkei 225

    25,776.06
    -161.15 (-0.62%)
     

Prothena to Participate in Upcoming Healthcare Conferences

·2 min read
Prothena Corporation plc
Prothena Corporation plc

DUBLIN, Ireland, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in the following upcoming investor conferences:

  • Citi’s 17th Annual BioPharma Conference on Thursday, September 8, 1x1 investor meetings will be held

  • Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, a fireside chat will be held at 5:15 PM ET

  • H.C. Wainwright 24th Annual Global Investment Conference on Wednesday, September 14, a fireside chat will be held at 9:00 AM ET

  • Cantor Neurology & Psychology Conference on Thursday, October 6, 1x1 investor meetings will be held

A live webcast of the fireside chats can be accessed through the investor relations section of the Company's website at www.prothena.com. Following the live presentation, a replay of the webcast will be available on the Company's website for at least 90 days following the presentation date.

About Prothena
Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a number of other neurodegenerative diseases. For more information, please visit the Company’s website at www.prothena.com and follow the Company on Twitter @ProthenaCorp.

Media and Investor Contact:

Investors
Jennifer Zibuda, Director, Investor Relations & Communications
650-837-8535, jennifer.zibuda@prothena.com

Media
Michael Bachner, Senior Director, Corporate Communications
609-664-7308, michael.bachner@prothena.com